Diarrhea after kidney transplantation: A new look at a frequent symptom

Transplantation

Volumn 98, Issue 8, 2014, Pages 806-816

  Aulagnon, Florence ^a,b   Scemla, Anne ^a,b   DeWolf, Susan ^c   Legendre, Christophe ^a,b,d,e,f   Zuber, Julien ^a,b,c,d,f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Department of Medicine   (United States)

^d CENTAURE Network   (France)

^e LabEx Transplantex   (France)

^f IMAGINE INSTITUTE   (France)

Author keywords

Diarrhea; Immunosuppressive drugs; Kidney transplantation; Norovirus

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN A; EVEROLIMUS; FUMAGILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IRON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; RAPAMYCIN; TACROLIMUS; TARGET OF RAPAMYCIN KINASE;

BACTERIAL INFECTION; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INTESTINE VILLUS ATROPHY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; THROMBOCYTOPENIA; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CALICIVIRUS INFECTION; COMPLICATION; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTION; NOROVIRUS; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

CALICIVIRIDAE INFECTIONS; CLOSTRIDIUM DIFFICILE; CRYPTOSPORIDIOSIS; CYTOMEGALOVIRUS INFECTIONS; DIARRHEA; HUMANS; KIDNEY TRANSPLANTATION; NOROVIRUS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84922014595     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000335     Document Type: Review

References (71)

1. Ekberg H, Kyllonen L, Madsen S, et al. Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologists. Transplantation 2007; 84: 1052.
2. Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis 2008; 51: 478.
3. Coste JF, Vuiblet V, Moustapha B, et al. Microbiological diagnosis of severe diarrhea in kidney transplant recipients by use of multiplex PCR assays. J Clin Microbiol 2013; 51: 1841.
4. Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation 2011; 92: 61.
5. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to cal-cineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
6. Ekberg H, Kyllonen L, Madsen S, et al. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients. Transplantation 2007; 83: 282.
7. Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated myco-phenolate sodium. Transplantation 2011; 92: 426.
8. Roddie C, Paul JP, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49: 1061.
9. Schwartz S, Vergoulidou M, Schreier E, et al. norovirus gastroenteritis causes severe and lethal complications after chemotherapy and he-matopoietic stem cell transplantation.Blood 2011; 117: 5850.
10. Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383.
11. Rankin AC, Walsh SB, Summers SA, et al. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant 2008; 8: 1755.
12. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
13. Takemoto SK, Pinsky BW, Schnitzler MA, et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients Am J Transplant 2007; 7: 2704.
14. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
15. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 1450.
16. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004; 364: 503.
17. Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium Nephrol Dial Transplant 2005; 20: 2231.
18. Knight SR, Russell NK, Barcena L, et al. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009; 87: 785.
19. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study Am J Transplant 2004; 4: 237.
20. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665.
21. Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol 2009; 22: 737.
22. Weclawiak H, Ould-Mohamed A, Bournet B, et al. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. Am J Transplant.
23. Dalle IJ, Maes BD, Geboes KP, et al. Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis 2005; 7: 27.
24. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009; 361: 1776.
25. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010; 141: 1135.
26. Heller T, van Gelder T, Budde K, et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients Am J Transplant 2007; 7: 1822.
27. Group TUSMFLS. A comparison of tacrolimus (FK 506) and cyclo-sporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994; 331: 1110.
28. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
29. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13: 277.
30. Veroux M, Grosso G, Ekser B, et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. Transplantation 2012; 93: 895.
31. Bamias G, Boletis J, Argyropoulos T, et al. Early ileocolonoscopy with biopsy for the evaluation of persistent post-transplantation diarrhea. World J Gastroenterol 2010; 16: 3834.
32. Arslan H, Inci EK, Azap OK, et al. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 2007; 9: 270.
33. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13: 260.
34. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946.
35. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435.
36. Li QR, Wang CY, Tang C, et al. Reciprocal interaction between intestinal microbiota and mucosal lymphocyte in cynomolgus monkeys after alemtuzumab treatment. Am J Transplant 2013; 13: 899.
37. Oh PL, Martinez I, Sun Y, et al. Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplants. Am J Transplant 2012; 12: 753.
38. Dubberke ER, Burdette SD. Clostridium difficile infections in solid organ transplantation. Am J Transplant 2013; 4: 42.
39. Boutros M, Al-Shaibi M, Chan G, et al. Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 2012; 93: 1051.
40. Peltekian KM. Clostridium difficile on the transplantation radar. Transplantation 2012; 93: 974.
41. Len O, Rodriguez-Pardo D, Gavalda J, et al. Outcome of Clostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort study. Transpl Int 2012; 25: 1275.
42. Friedman-Moraco RJ, Mehta AK, Lyon GM, et al. Fecal Microbiota Transplantation for Refractory Clostridium difficile Colitis in Solid Organ Transplant Recipients. Am J Transplant. 2014.
43. Imai N, Uchida D, Hanada M, et al. A case of Campylobacter enteritis in a renal transplant recipient. Transplantation 2013; 95: e78.
44. Maes B, Hadaya K, de Moor B, et al. Severe diarrhea in renal transplant patients: results of the DIDACT study. Am J Transplant 2006; 6: 1466.
45. Grim SA, Pereira E, Guzman G, et al. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010; 90: 799.
46. Durand CM, Marr KA, Arnold CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis 2013; 57: 1550.
47. Asberg A, Jardine AG, Bignamini AA, et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010; 10: 1881.
48. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2012; 367: 2126.
49. Schorn R, Hohne M, Meerbach A, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis 2010; 51: 307.
50. Westhoff TH, Vergoulidou M, Loddenkemper C, et al. Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant 2009; 24: 1051.
51. Kaufman SS, Chatterjee NK, Fuschino ME, et al. Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant 2003; 3: 764.
52. Atmar RL, Bernstein DI, Harro CD, et al. norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365: 2178.
53. Chang KO, George DW. Interferons and ribavirin effectively inhibit Nor-walk virus replication in replicon-bearing cells. J Virol 2007; 81: 12111.
54. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther 2006; 24: 1423.
55. Florescu DF, Hill LA, McCartan MA, et al. Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr Transplant 2008; 12: 372.
56. Engelen MA, Gunia S, StypmannJ. Elimination of norovirus in a chronic carrier under immunosuppression after heart transplantationVeffect of everolimus. Tr a n s p l I n t 2011; 24: e102.
57. Florescu MC, Miles CD, Florescu DF. What do we know about adeno-virus in renal transplantation? Nephrol Dial Transplant 2013; 28: 2003.
58. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of ade-novirus infection in adult solid organ transplant recipients. Am J Transplant 2005; 5: 2555.
59. Stelzmueller I, Wiesmayr S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem?. Transpl Infect Dis 2007; 9: 281.
60. Champion L, Durrbach A, Lang P, et al. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. Am J Transplant 2010; 10: 1925.
61. Lanternier F, Boutboul D, Menotti J, et al. Microsporidiosis in solid organ transplant recipients: two Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009; 11: 83.
62. Bandin F, Kwon T, Linas MD, et al. Cryptosporidiosis in paediatric renal transplantation. Pediatr Nephrol 2009; 24: 2245.
63. Campos M, Jouzdani E, Sempoux C, et al. Sclerosing cholangitis associated to cryptosporidiosis in liver-transplanted children. Eur J Pediatr 2000; 159: 113.
64. Minz M, Udgiri NK, Heer MK, et al. Cryptosporidiasis in live related renal transplant recipients: a single center experience. Transplantation 2004; 77: 1916.
65. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
66. Rice JP, Spier BJ, Cornett DD, et al. Utility of colonoscopy in the evaluation of diarrhea in solid organ transplant recipients. Transplantation 2009; 88: 374.
67. Nepal S, Navaneethan U, Bennett AE, Shen B. De novo inflammatory bowel disease and its mimics after organ transplantation. Inflamm Bowel Dis 2013; 19: 1518.
68. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431.
69. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13: 24; quiz
70. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
71. Chehade H, Girardin E, Delich V, et al. Acute norovirus-induced agranulocytosis in a pediatric kidney transplant recipient. Transpl Infect Dis 2012; 14: E27.